Biosim AI strives to significantly reduce the time for small-molecule drug discovery from years to months with the help of advanced computational methods and artificial intelligence. The company is based in the Boston area and was founded in 2020 by Garegin Papoian, an expert in Theoretical and Computational Chemistry and Biophysics and current Biosim AI CEO.

Biosim

FDA write-up reveals production flaws behind Alvotech's recent Humira biosim slapdown - FiercePharma

Momenta ramps up biosim pressure on AbbVie's Humira with phase 3 psoriasis win - FiercePharma

Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise - FiercePharma

Sandoz taps Evotec in long-term biosimilar development and manufacturing deal - FiercePharma

AbbVie says manufacturing will be key differentiator between Humira's biosimilar competitors - FiercePharma

Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. - FiercePharma

Coherus' newly minted Neulasta biosim steps up pressure on Amgen - FiercePharma

Roche's Herceptin one step closer to biosim battle with Mylan licensing deal - FiercePharma

Sandoz reveals plan to boost global biosim uptake, starting in the Americas - FiercePharma

Partnerships for the planet: bioSIM - MTN Group

Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval - FiercePharma

Lilly's Lantus biosim arrives to poach already hard-hit Sanofi sales - FiercePharma

Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed terms - FiercePharma

Johnson & Johnson inks another Stelara patent settlement, this time with Alvotech and Teva - FiercePharma

Sandoz's Enbrel biosim case turned away at SCOTUS, giving Amgen's blockbuster 8 more years of free rein - FiercePharma

Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24% - FiercePharma

AbbVie inks yet another Humira biosim deal—this time with Novartis—as EU launches near - FiercePharma

J&J braces for biosim attack after losing last-ditch Remicade patent fight - FiercePharma

J&J pooh-poohs threat from Remicade biosim this year - FiercePharma

For Biocon Biologics' CEO, the Humira biosimilar clash isn't only about market share - FiercePharma

Amgen’s Humira biosim clears EMA regulatory hurdle - BioPharma Dive

Amgen reaps Horizon buyout rewards in Q3 as it gears up for key biosim launches - FiercePharma

Sandoz delivers 6% sales growth with Humira biosimilar leading the charge - FiercePharma

Coherus sells Lucentis biosim to Sandoz for $170M to focus on oncology - FiercePharma

The first Humira biosim is doing Amgen more harm than good—for now - FiercePharma

Italy opens antitrust case against Novartis, Roche and others, claiming collusion to delay biosim launch - FiercePharma

UMD Drug Development Startup Biosim AI Raises over $12 Million - citybiz

Evernorth's Accredo to offer Humira biosimilar at $0 out-of-pocket - Fierce healthcare

Backed by Indian biosim giant Biocon, bispecifics player Bicara debuts with $40M and solid tumors on the radar - Endpoints News

Ocrevus, Hemlibra offset Roche's biosim loss. But what about those lackluster Xofluza sales? - FiercePharma

How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal - FiercePharma

J&J, under 'accelerating' generic and biosim attack, expects growth to bottom out in 2019 - FiercePharma

Aiming to shield $14B in sales, AbbVie smacks Amgen with a patent suit over Humira biosim - FiercePharma

Roche yields to cancer biosim competition by offering 'relevant' discounts: report - FiercePharma

Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst - FiercePharma

Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year - FiercePharma

Mylan's Herceptin biosim matches Roche original in safety, efficacy study - FiercePharma

Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet - FiercePharma

Sandoz, nearing Novartis split, signs up to commercialize Samsung Bioepis' Stelara biosimilar - FiercePharma

Fierce Pharma Asia—Takeda's cancer drug withdrawal; Kyowa Kirin's gene therapy buy; Biogen's biosim nod - FiercePharma

Novartis wins FDA nod for first biosimilar version of Biogen's MS blockbuster Tysabri - FiercePharma

AbbVie says biosim maker Alvotech recruited a manufacturing exec to steal trade secrets on Humira - FiercePharma

Roche hit by worst-case biosim assault—to the tune of $5.6B—as COVID-19 hurts new king Ocrevus - FiercePharma

Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch - FiercePharma

Pfizer's new Inflectra biosim data puts J&J's Remicade on notice in Crohn's - FiercePharma

With Amgen's biosim on the scene, J&J's Stelara looks poised to sidestep Medicare negotiations: HHS - FiercePharma

Teva's July launch for Humira biosimilar in jeopardy after Alvotech's 2nd rejection - FiercePharma

Pfizer's Herceptin biosim posts 'encouraging' phase 3 data in blockbuster sales battle - FiercePharma

As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model - FiercePharma

IRA biosimilar measure intended to boost uptake so far has 'limited' impact: report - FiercePharma

Biosim

Business:

About: